<?xml version="1.0" encoding="UTF-8"?>
<p>The epidemic potential of mosquitoes transmitted ZIKV likely increased epidemic and infects tens of thousands of people (
 <xref rid="B5" ref-type="bibr">Baud et al., 2017</xref>; 
 <xref rid="B47" ref-type="bibr">Yadav et al., 2019</xref>). More seriously, a recent study uncovered a hidden outbreak in Cuba during the year 2017 and highlights that ZIKV may still be silently spreading worldwide (
 <xref rid="B17" ref-type="bibr">Grubaugh et al., 2019</xref>). Currently, no effective vaccines or antiviral drugs have been approved for ZIKV. Venom systems have been used for predation and defense and venom-derived peptides have become an important source of antivirals (
 <xref rid="B9" ref-type="bibr">Cecilio et al., 2013</xref>; 
 <xref rid="B22" ref-type="bibr">Hong et al., 2014</xref>; 
 <xref rid="B21" ref-type="bibr">Holthausen et al., 2017</xref>; 
 <xref rid="B23" ref-type="bibr">Ji et al., 2019</xref>). For example, a representative defensin-like antiviral peptide BmKDfsin4 from the scorpion 
 <italic>Mesobuthus martensii</italic> Karsch was reported to inhibit Hepatitis B virus replication (
 <xref rid="B49" ref-type="bibr">Zeng et al., 2016</xref>). However, natural antiviral peptides sometimes have some drawbacks for their further clinical use (
 <xref rid="B7" ref-type="bibr">Boto et al., 2018</xref>). Therefore, developing natural peptides derived analogs with improved pharmacological properties and reduced side effects is imperative (
 <xref rid="B14" ref-type="bibr">Fjell et al., 2011</xref>; 
 <xref rid="B24" ref-type="bibr">Jin et al., 2016</xref>; 
 <xref rid="B7" ref-type="bibr">Boto et al., 2018</xref>).
</p>
